Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
334 participants
OBSERVATIONAL
2019-03-21
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective and Prospective Observational Study in Patients With Advanced Basal Cell Carcinoma
NCT06309836
Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions
NCT05907551
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
NCT05878964
Observational Study in Localized Osteosarcoma
NCT04890067
Itch and Pain Characteristics in Skin Carcinomas
NCT03290989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will follow the prescribed therapeutic indications according to regular clinical practice and data from their medical records will be collected in a study database.
Primary objective of the study is the evaluation of the type, frequency and severity of skin toxicities related to oncological treatment.
Secondary objectives are:
* Evaluation of the association between skin toxicities due to oncological treatment and drug activity and effectiveness parameters(ORR, PFS, OS);
* Evaluation of the association between clinical-pathological features of primary cancer and skin toxicities of oncological treatment;
* Evaluation of the optimal management of skin toxicities related to cancer treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Consecutive retrospective patients and prospective patients treated with new clinical practice oncological treatments (approved by AIFA) from January 2012 to February 2024
3. Male or female, age ≥18 years.
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matelda Medri, PhD
Role: STUDY_CHAIR
IRST IRCCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedale "Franz Tappeiner"
Merano, Bolzano, Italy
AUSL della Romagna - Ospedale "M. Bufalini"
Cesena, Forlì-Cesena, Italy
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
Meldola, Forlì-Cesena, Italy
Sapienza Università di Roma - Polo Pontino
Terracina, Latina, Italy
Centro di Riferimento Oncologico
Aviano, Pordenone, Italy
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
Bari, , Italy
IRCCS Istituto Tumori "Giovanni Paolo II"
Bari, , Italy
Università di Bologna
Bologna, , Italy
Università "G. D'Annunzio"
Chieti, , Italy
Azienda USL Toscana Centro
Florence, , Italy
ASL di Frosinone - Ospedale "Fabrizio Spaziani"
Frosinone, , Italy
Azienda Ospedaliera "Papardo"
Messina, , Italy
IRCCS Istituto Nazionale dei Tumori
Milan, , Italy
Istituto Europe di Oncologia
Milan, , Italy
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
Napoli, , Italy
Università della Campania "Luigi Vanvitelli"
Napoli, , Italy
Università Campus Bio-Medico
Roma, , Italy
Università degli Studi di Salerno AOU san Giovanni di Dio e Ruggi D'Aragona
Salerno, , Italy
Azienda Ospedaliera Universitaria Senese
Siena, , Italy
AOU Città della Salute e della Scienza
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRST100.41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.